Shandong Bailong Chuangyuan Bio-Tech Future Growth
Future criteria checks 5/6
Shandong Bailong Chuangyuan Bio-Tech is forecast to grow earnings and revenue by 30.6% and 27.6% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 18.7% in 3 years.
Key information
30.6%
Earnings growth rate
30.3%
EPS growth rate
| Food earnings growth | 22.3% |
| Revenue growth rate | 27.6% |
| Future return on equity | 18.7% |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,952 | 470 | 290 | 406 | 3 |
| 12/31/2025 | 1,561 | 365 | 218 | 319 | 3 |
| 12/31/2024 | 1,197 | 271 | -169 | 73 | 3 |
| 9/30/2024 | 1,035 | 234 | -65 | 217 | N/A |
| 6/30/2024 | 987 | 221 | -44 | 191 | N/A |
| 3/31/2024 | 926 | 202 | -123 | 201 | N/A |
| 12/31/2023 | 868 | 193 | -117 | 195 | N/A |
| 9/30/2023 | 825 | 174 | -70 | 187 | N/A |
| 6/30/2023 | 742 | 163 | -29 | 191 | N/A |
| 3/31/2023 | 719 | 154 | -9 | 167 | N/A |
| 12/31/2022 | 722 | 151 | -26 | 150 | N/A |
| 9/30/2022 | 732 | 147 | -40 | 141 | N/A |
| 6/30/2022 | 739 | 131 | -13 | 143 | N/A |
| 3/31/2022 | 717 | 128 | -10 | 95 | N/A |
| 12/31/2021 | 653 | 104 | 40 | 96 | N/A |
| 9/30/2021 | 605 | 99 | -15 | 51 | N/A |
| 6/30/2021 | 566 | 97 | -33 | 32 | N/A |
| 3/31/2021 | 540 | 98 | 46 | 119 | N/A |
| 12/31/2020 | 500 | 96 | 37 | 122 | N/A |
| 9/30/2020 | 479 | 93 | 83 | 150 | N/A |
| 6/30/2020 | 464 | 92 | 75 | 138 | N/A |
| 3/31/2020 | 416 | 77 | -1 | 58 | N/A |
| 12/31/2019 | 421 | 83 | 8 | 64 | N/A |
| 12/31/2018 | 356 | 65 | 1 | 89 | N/A |
| 12/31/2017 | 311 | 64 | N/A | 113 | N/A |
| 12/31/2016 | 336 | 65 | N/A | 60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 605016's forecast earnings growth (30.6% per year) is above the savings rate (2.8%).
Earnings vs Market: 605016's earnings (30.6% per year) are forecast to grow faster than the CN market (25.9% per year).
High Growth Earnings: 605016's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 605016's revenue (27.6% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 605016's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 605016's Return on Equity is forecast to be low in 3 years time (18.7%).